Mynosys Cellular Devices Inc. Receives Import Authority From South Korea for Zepto®

Share Article

Mynosys Cellular Devices Inc. receives import authority from South Korea and announces Zepto® entry into the South Korean market

Mynosys Cellular Devices is pleased to announce that it has received a Medical Device Import Certificate from the South Korean Ministry of Food and Drug Safety for its flagship automated capsulotomy product, Zepto®. “This import authority was granted in December 2017 and allows Mynosys to begin selling the Zepto Capsulotomy System in this dynamic Asian market,” says John Hendrick, CEO and President of Mynosys. “The reception Zepto® has received from surgeons at the recent Korean Ophthalmological Society meeting was tremendous. Over 200 physicians visited the exhibit booth to learn about Zepto® and were impressed with both its simplicity and versatility.” Mr. Hendrick also added that “Many of the teaching institutions also immediately recognized the impact Zepto® can have on the training of cataract surgeons in South Korea.”

Zepto® is distributed in South Korea by HKT Co. Ltd. Hui Hwang, CEO of HKT remarked, “We experienced an extraordinarily high level of surgeon interest in Zepto® when it was showcased at the Korean Ophthalmological Society meeting.” “Professor Joo Choun-Ki of The Catholic University of Korea had in fact expressed an early interest in Zepto® technology and had traveled to the United States to learn about Zepto® from John and his team,” said Hwang. “Professor Joo recently performed the first cases of Zepto® cataract surgery in South Korea and achieved excellent results.” Hwang further explained, “Zepto® is very attractive to surgeons given its ability to consistently deliver high quality, strong capsulotomies in routine, challenging, and premium cases. In addition, with the added patient benefit of having a personalized cataract surgery anchored on the visual axis using Zepto-guided visual axis centration, we are anticipating strong acceptance of this innovative product in the South Korean market.”

Zepto® is CE Marked and FDA cleared. It is available through distributors in selected countries internationally and in the United States.

Contact; Dr. Pat Lydon

Research was supported by the National Eye Institute / National Institutes of Health under award no. R44EY021023. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Hendrick
Visit website